Comparing the First and Second Wave of COVID-19 in Kidney Transplant Recipients: An East-European Perspective

Florin Ioan Elec\textsuperscript{a, b} Sorana D. Bolboac\v{a}\textsuperscript{c} Adriana Muntean\textsuperscript{a} Alina Daciana Elec\textsuperscript{a} Cristina Cismaru\textsuperscript{d} Mihaela Lup\v{s}e\textsuperscript{d} Mihai Oltean\textsuperscript{e, f}

\textsuperscript{a}Clinical Institute of Urology and Renal Transplantation, Cluj-Napoca, Romania; \textsuperscript{b}Department of Urology, University of Medicine and Pharmacy, Cluj-Napoca, Romania; \textsuperscript{c}Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy, Cluj-Napoca, Romania; \textsuperscript{d}Department of Infectious Diseases, University of Medicine and Pharmacy, Cluj-Napoca, Romania; \textsuperscript{e}Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden; \textsuperscript{f}Department of Surgery, Institute for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Keywords
COVID-19 · Epidemic wave · Kidney transplantation · Outcome

Abstract

Background: The present study examined whether patient characteristics, management, and outcome of kidney transplant recipients (KTx) with COVID-19 changed in the second versus the first pandemic wave. Methods: We reviewed all available data (demographics, medical history, comorbidities, therapeutic interventions, and outcome) on our KTx with COVID-19 during the first wave (March–September 2020, \textit{n} = 33) and the second wave (October 2020–February 2021, \textit{n} = 149) of the COVID-19 pandemic. Results: One hundred eighty-two out of our 1,503 KTx in active follow-up got COVID-19 during 12-month period, corresponding to a prevalence of 12.1\%. No difference was found in age, gender distribution, comorbidities, body mass index, or baseline immunosuppression between the 2 COVID-19 waves. Bilateral COVID pneumonia was more frequent during the first wave. More KTx were managed as outpatients during the second wave (15 vs. 39\%, \textit{p} < 0.01). Calcineurin inhibitors were more sparingly reduced during the second wave, whereas antimetabolites were similarly reduced (91 vs. 86, \textit{p} = ns). Admission to intensive care units was comparable between the first (27\%) and second waves (23\%). During the first wave, 8 out of 9 patients (89\%) requiring intensive care died, whereas the mortality of the ICU patients in the second wave was 68\% (23 deaths) (\textit{p} = 0.2). The overall mortality was 24\% during the first wave and 16\% during the second wave (\textit{p} = 0.21), while in-hospital mortality was identical between the COVID-19 waves (27\%). Increasing age and poor allograft function were significant predictors of mortality. Conclusions: Most patient characteristics and outcome were comparable between the first 2 COVID-19 waves. More KTx were managed as outpatients without an overall negative impact on outcome.

Introduction

COVID-19 pandemic has claimed millions of lives and wreaked havoc on all aspects of human society. The early response in the spring of 2020 combined regional and national lockdowns, wearing face masks, curtailing indoor and outdoor activities, and imposing severe travel restric-
COVID-19 pandemic at an East-European kidney transplant center. Therefore, it is likely that COVID-19 cases in this patient group are promptly self-reported and come following COVID-19 infection [3–5]. Given the need for a regular follow-up, transplanted patients usually maintain a close and frequent contact with their transplant center. Therefore, it is likely that COVID-19 cases in this patient group are promptly self-reported and more accurately identified, allowing for more correct insights into the frequency and outcome of the disease.

An increasing number of publications suggest that several differences may have existed in terms of epidemiology and outcome between the first and second COVID-19 waves [6–9]. The improved testing capacity and the increased knowledge about the pathology and treatment of COVID-19 but also the emergence of mutant virus strains may have been responsible for the different patterns increasingly reported in various settings. The limited data comparing the first and second waves of the COVID-19 in kidney transplant recipients (KTx) reveal diverging results between countries and have several significant limitations such as few patients or a selection bias toward hospitalized cases [10, 11]. We hereby present a comparison between the first and second waves of the COVID-19 pandemic at an East-European kidney transplant center, after the remission of the second wave.

**Patients and Methods**

**Patient Selection**

We performed a retrospective review of all patients who underwent kidney transplantation at the Clinical Institute of Urology and Renal Transplantation in Cluj-Napoca, Romania, who got sick with COVID-19 during the first and second waves of the COVID-19 pandemic. SARS-CoV-2 infection was defined as a positive result for SARS-CoV-2 RNA on real-time polymerase chain reaction assay of a nasopharyngeal swab. Both asymptomatic KTx and patients developing typical symptoms such as temperature >38°C, respiratory, gastrointestinal, neurological, or general symptoms were included.

For the purpose of this article, the first wave of the pandemic was defined as the interval between the first reported case in Romania (February 26, 2020) and the start of the second wave. The start of the second wave was defined by a sustained 25% increase in new weekly cases compared with the previous week (September 28, 2020). The second wave was considered to have lasted until the week with the lowest number of new cases reported since the start of the second wave (February 14, 2021).

**Patient Management**

The COVID-19 treatment protocol recommended in Romania in the early phase of the pandemic (March–July 2020) was based on hydroxychloroquine and antiretrovirals, as previously described [12]. Antiretrovirals (lopinavir/ritonavir, darunavir/ritonavir, or darunavir/cobicistat) were added in patients with mild and moderate forms and adequate renal function (GFR >30 mL/min/1.73 m²). From mid-July 2020, dexamethasone and remdesivir (and favipiravir, from late 2020) were added to the treatment protocol in more severe cases, whereas hydroxychloroquine and antiretrovirals were no longer recommended. Antibiotics were also given at the discretion of the medical teams attending the patients. The use of anticoagulation using low molecular weight heparin was recommended in hospitalized patients from mid-April 2020 onward.

Immunosuppression was reduced by withdrawing the antimeabolite (mycophenolate mofetil or mycophenolic acid) with or without adjustment of calcineurin inhibitors. Tacrolimus was withdrawn in all patients receiving antiretrovirals and adjusted to maintain a trough level of 4–6 ng/mL in the other patients. Steroids were either kept at the maintenance dose or converted to IV for stress dosing.

All available medical records were reviewed and data on demographics, medical history, comorbidities, therapeutic interventions (antivirals, changes in immunosuppression, corticosteroid therapies, and respiratory support), and outcomes were collected and analyzed. Disease severity was classified from mild to critical [13]. The comorbidity assessment was performed using the age-adjusted Charlson comorbidity index as previously described [14]. Charlson comorbidity index includes 19 different medical conditions, and each comorbid disorder is ranged from 1 to 6 points to sum an index score. Additional points were added for age, and each decade over the age of 50 years received 1 point. Kidney graft function (estimated glomerular filtration rate) was assessed on data collected 12 months before COVID-19 using the CKD-EPI formula. The study was approved by the Institutional Review Board of the Clinical Institute of Urology and Renal Transplantation (1/2021).
Table 1. Patient baseline data, COVID-19 management, and outcome

|                                | All patients  | First wave  | Second wave | p value |
|--------------------------------|---------------|-------------|-------------|---------|
|                                | (n = 182)     | (n = 33)    | (n = 149)   |         |
| Males                          | 120 (65.9)    | 24 (72.7)   | 96 (64.4)   | 0.363   |
| Age, years                     | 51 (43–57)    | 52 (46–58)  | 50 (43–56)  | 0.544   |
| Months from transplant         | 93.5 (38.5–139.3) | 91 (34–150) | 94 (45–136) | 0.695   |
| First year after transplant    | 11 (6.0)      | 3 (9.1)     | 8 (5.4)     | 0.638   |
| BMI, kg/m²                     | 26.6 (18.7–40.6) | 27 (20.7–35.3) | 26.4 (18.7–40.6) | 0.209   |
| CCI median, range              | 3 (2–4)       | 3 (2–4)     | 3 (2–4)     | 0.968   |
| CCI 2                          | 69 (37.9)     | 12 (36.3)   | 57 (38.2)   | 0.756   |
| CCI 3 or 4                     | 90 (49.4)     | 18 (54.5)   | 72 (48.3)   |         |
| CCI 5 and over                 | 23 (12.6)     | 3 (9.0)     | 20 (13.4)   |         |
| Comorbidities                  |               |             |             |         |
| Hypertension                   | 144 (79.1)    | 24 (72.7)   | 120 (80.5)  | 0.318   |
| Diabetes                       | 48 (26.3)     | 8 (24.2)    | 40 (26.8)   | 0.759   |
| Cardiovascular                 | 59 (32.4)     | 9 (27.2)    | 50 (33.5)   | 0.485   |
| Malignancy                     | 8 (4.3)       | 8 (5.3)     | n/a         |         |
| Dementia                       | 1 (0.5)       | 1 (3.0)     | n/a         |         |
| Obesity                        | 35 (19.2)     | 7 (21.2)    | 28 (18.7)   | 0.750   |
| Baseline BMI, kg/m²            | 26.6 (18.7–40.6) | 27 (20.7–35.3) | 26.4 (18.7–40.6) | 0.209   |
| Baseline eGFR, median/range    | 49 (32.8–70.3) | 53 (40–72)  | 49 (31–68.5) | 0.265   |
| Baseline immunosuppression a   |               |             |             |         |
| Triple regimen                 | 138 (75.8)    | 26 (78.7)   | 112 (75.1)  | 0.62    |
| Tacrolimus                      | 152 (83.5)    | 30 (90.9)   | 122 (81.8)  | 0.2     |
| Cyclosporine A                 | 3 (1.6)       | 1 (3.0)     | 2 (1.3)     | 0.37    |
| Rapamycin                      | 4 (2.1)       | 4 (2.6)     | n/a         |         |
| Antimetabolites                | 177 (97.2)    | 33 (100)    | 144 (96.6)  | 0.31    |
| Low-dose steroids              | 165 (90.6)    | 28 (84.8)   | 137 (91.9)  | 0.21    |
| Disease severity               |               |             |             |         |
| Mild                            | 73 (40.1)     | 13 (39.3)   | 60 (40.2)   | 0.93    |
| Moderate                       | 35 (19.2)     | 6 (18.1)    | 29 (19.4)   | 0.87    |
| Severe                          | 33 (18.1)     | 7 (21.2)    | 26 (17.4)   | 0.61    |
| Critical                       | 41 (22.5)     | 7 (21.2)    | 34 (22.8)   | 0.84    |
| Radiological findings          |               |             |             |         |
| Abnormal findings (all types)  | 119/133 (89.4) | 25/28 (89.2) | 94/105 (89.5) | 0.963   |
| COVID-19 pneumonia             | 86/133 (64.6) | 22/28 (78.5) | 64/105 (60.9) | 0.08    |
| Bilateral pneumonia            | 54/86 (62.7)  | 22/22 (100) | 32/64 (50)  | <0.001  |
| Outpatient                     | 63 (34.6)     | 5 (15.1)    | 58 (38.9)   | 0.008   |
| COVID-19 management            |               |             |             |         |
| MMF reduction/withdrawal       | 158 (86.8)    | 30 (90.9)   | 128 (85.9)  | 0.44    |
| CNI reduction/withdrawal       | 68 (37.3)     | 20 (60.6)   | 48 (32.2)   | 0.001   |
| HCQ                            | 27 (14.8)     | 13 (39.3)   | 14 (9.3)    | <0.001  |
| Tocilizumab                    | 8 (4.3)       | 1 (3.0)     | 7 (4.6)     | 0.62    |
| Dexamethasone                  | 74 (40.6)     | 15 (45.4)   | 59 (39.5)   | 0.59    |
| Antiretrovirals                | 18 (9.8)      | 8 (24.2)    | 10 (6.7)    | 0.003   |
| Remdesivir/favipiravir         | 38 (20.8)     | 5 (15.1)    | 33 (22.1)   | 0.37    |
| Oxygen therapy                 | 75 (41.2)     | 14 (42.4)   | 61 (40.9)   | 0.91    |
| LMWH and NOAC                  | 118 (64.8)    | 26 (78.7)   | 92 (61.7)   | 0.06    |
| CRRT                           | 7 (3.8)       | 7 (4.6)     | 19 (12.5)   | 0.19    |
| Intensive care admission       | 43 (23.6)     | 9 (27.2)    | 34 (22.8)   | 0.62    |
| Outcome                        |               |             |             |         |
| Discharged                     | 88/119 (73.94) | 20/28 (71.4) | 68/91 (74.7) | 0.67    |
| Dead                           | 31/182 (17.0) | 8/33 (24.2) | 23/149 (15.4) | 0.22    |

Data are reported as number/total number of available observations and (percent), or median and interquartile range (Q1Q3) and were analyzed with n/a, not applicable; CCI, Charlson comorbidity index; CNI, calcineurin inhibitors; CRRT, continuous renal replacement therapy; HCQ, hydroxychloroquine; LMWH, low molecular weight heparin; MMF, mycophenolate mofetil; NOAC, nonvitamin K antagonist oral anticoagulants; eGFR, estimated glomerular filtration rate. a χ² test or Fisher’s exact test. b Mann-Whitney test.
Results

Patients

At the start of the COVID-19 pandemic, there were 1,467 KTx recipients alive and in follow-up at the Institute for Urology and Renal Transplantation in Cluj-Napoca. An additional 36 patients were transplanted during the study period, resulting in 1,503 KTx recipients at potential risk. In total, 182 KTx got sick with COVID-19 during the study period, corresponding to a prevalence of 12.1%.

Overall, the median patient age was 51 years and males represented 65.9% of the entire cohort. Ten patients (5.4%) received their transplants in the 12 months before their COVID-19 infection. Thirty-three KTx got sick with COVID-19 before October 1, 2020 (the first wave), whereas 149 KTx got infected after this date (the second wave). The characteristics of all 182 SARS-CoV-2-positive KTx recipients are detailed in Table 1, both as a single patient cohort and separately as 2 subgroups, according to the onset of COVID-19.

There was no significant difference in age, gender distribution, comorbidities, body mass index, or in terms of immunosuppression between the patients of the first and second COVID waves. Disease severity (i.e., mild, moderate, severe, and critical) was similar between the 2 outbreaks. However, KTx in the first wave had a trend toward more frequently developing COVID-19 pneumonia and had significantly higher bilateral pulmonary involvement.

Management

Patient management differed in many respects between the 2 waves, reflecting changing health policies and guidelines, accumulating knowledge about COVID-19, and increasing experience. Significantly more patients were managed on outpatient basis during the second wave (15 vs. 39%, p < 0.01). Hydroxychloroquine and antiretrovirals were all but abandoned during the second wave. A trend toward a lesser use of anticoagulants was also observed during the second wave (Table 1).

Likewise, immunosuppression was managed differently during the second COVID wave. Whereas antimetabolites were reduced in a similar proportion (91 vs. 86, p > 0.05), calcineurin inhibitors were more sparingly reduced or withheld during the second wave. The proportion of patients with unchanged immunosuppression remained similar and low (9 vs. 7%, p > 0.05). Around 40% of the transplanted patients developing COVID-19 required oxygen therapy in different forms, whereas 1 quarter were admitted to intensive care units similarly between the first (27%) and second waves (23%).

Outcome

Overall mortality was 24% during the first wave and 16% during the second wave (p = 0.21). Mortality for hospitalized patients was identical during both COVID-19 waves (27%). During the first wave, 8 out of 9 patients (89%) requiring intensive care died, whereas the mortality of the ICU patients in the second wave was 68% (23 deaths) (p = 0.2).

In the univariate analysis, age, baseline eGFR, increasing comorbidities, and hypertension proved to be significant independent predictors for death for the whole cohort (Table 2). Baseline estimated glomerular filtration rate remained a significant prognostic factor in both waves, whereas age remained significant only in the second wave where the sample was larger (Table 3). No episode of acute rejection and no graft loss were recorded after at least 2 months of follow-up.

Discussion

Most of the published information on COVID-19 has been based on the data obtained over the first half year of the outbreak during “the first wave” of the pandemic, when the entire scientific and medical community rushed to understand and manage this complex and potentially lethal disease. Several risk factors such as male gender, advanced age, and some concurrent diseases and medications have been identified as risk factors for complicated disease or unfavorable outcomes [15–17]. However, the reappearance of a second outbreak of infections in the fall...
COVID-19 in Kidney Transplant Recipients

Eur Surg Res 2022;63:25–32
DOI: 10.1159/000517559

of 2020, greatly surpassing the first wave in terms of number of infections and hospitalizations, raises several new questions whether “the second wave” follows a different pattern in comparison with the initial, first outbreak. Preliminary reports from Italy suggest that the second COVID-19 wave is less severe and deadly than the first one (8) but also that the demographics of patients who died with COVID-19, their treatment, and disease trajectory have largely changed over time [18].

Several early reports signaled that transplant recipients with COVID-19 ran a very high risk of unfavorable outcome [3, 19–21]. Besides several controversial interventions (i.e., hydroxychloroquine and antiretrovirals), decreasing immunosuppression was advocated already in the early days of the COVID-19 outbreak [20, 22]. However, as evidence and guidelines were initially lacking, reducing immunosuppression varied significantly between centers (from modest reductions to complete interruption), whereas the low number of patients precluded any substantial conclusions on the efficacy of any particular approach. As the evidence and experience accumulated, several guidelines were ultimately issued and immunosuppression management during COVID-19 has become more rational and structured [23]. Our analysis confirms a trend toward a more restrictive and rational approach of immunosuppression reduction, particularly that of calcineurin inhibitors during the second COVID-19 wave, which did not negatively impact the outcomes. The feasibility of outpatient management of transplanted COVID-19 patients has been shown during the first wave of the pandemic [24–26]. In the current patient group, increasingly managing the COVID-19 patients on an outpatient basis appeared as the single most significant change in patient management between the first and second COVID-19 waves. The proportion of patients managed entirely as outpatients was similar to that of a large Swedish cohort [27]. Although we could not retrieve reliable data on KTxs initially managed as outpatients and later progressing and requiring hospitalization, published data suggest that about a third of the patients initially managed as outpatients ultimately require hospitalization [25, 27]. This underscores the importance of recognizing the risk factors for progression toward hospitalization and the essential role of accurate self-monitoring and telemedicine [28], as the trend to initially manage transplanted COVID-19 patients with mild symptoms at home is likely to continue.

Table 2. Unadjusted univariate logistic regression analysis for death as outcome after COVID-19 for the entire cohort of KTxs, and by waves

|                      | All patients (n = 182) | First wave (n = 33) | Second wave (n = 149) |
|----------------------|-----------------------|---------------------|-----------------------|
|                      | OR [95% CI] p value    | OR [95% CI] p value | OR [95% CI] p value   |
| Age (years)          | 1.06 [1.02–1.11] 0.006 | 1.08 (0.98–1.18) 0.114 | 1.06 (1.01–1.11) 0.030 |
| Male                 | 0.93 [0.41–2.08] 0.855 | 0.53 (0.1–2.88) 0.459 | 1.04 (0.41–2.65) 0.932 |
| BMI (kg/m²)          | 1.02 [0.92–1.12] 0.716 | 1.01 (0.8–1.27) 0.933 | 1.1 (0.91–1.13) 0.798 |
| Months after transplant | 1.00 [0.997–1.01] 0.324 | 1 (0.99–1.01) 0.775 | 1 (1–1.01) 0.311 |
| CCI                  |                      |                      |                      |
| 2 (reference)        |                      | 0.156               |                      |
| 3 or 4               | 3.66 [1.30–10.32] 0.014 | 4.23 (0.43–41.87) 0.217 | 3.49 (1.09–11.17) 0.036 |
| 5+                   | 4.52 [1.23–16.61] 0.023 | 22 (0.94–515.87) 0.055 | 3.31 (0.74–14.76) 0.116 |
| eGFR at baseline     | 0.95 [0.93–0.97] <0.001 | 0.94 (0.89–0.99) 0.029 | 0.95 (0.92–0.97) <0.001 |
| Obesity              | 1.01 [0.38–2.69] 0.985 | 0.45 (0.05–4.46) 0.497 | 1.24 (0.42–3.7) 0.694 |
| Hypertension         | 4.54 [1.03–19.96] 0.045 | 807,737,466.81 (0–0) 0.999 | 2.86 (0.63–12.98) 0.172 |
| Diabetes             | 1.18 [0.50–2.77] 0.712 | 5.25 (0.91–30.22) 0.063 | 0.72 (0.25–2.09) 0.549 |
| Antiviral            |                      |                      |                      |
| None (reference)     |                      | 0.334               |                      |
| Antiretrovirals      | 2.37 [0.75–7.49] 0.142 | 1.33 (0.19–9.27) 0.771 | 3.07 (0.69–13.6) 0.140 |
| Remdesivir/favipiravir | 1.28 [0.49–3.33] 0.608 | 2.67 (0.33–21.73) 0.360 | 1.1 (0.37–3.28) 0.871 |
| Immunomodulatory     | 0.97 [0.37–2.57] 0.948 | 0.36 (0.06–2.15) 0.263 | 1.26 (0.39–4.14) 0.700 |
| Corticosteroids      | 1.28 [0.59–2.80] 0.529 | 0.42 (0.07–2.53) 0.346 | 1.77 (0.73–4.33) 0.209 |
| Anticoagulants       | 1.95 [0.82–4.64] 0.132 | 0.95 (0.15–5.99) 0.954 | 2.19 (0.81–5.94) 0.122 |
| ACE inhibitors/ARB   | 1.17 [0.44–3.08] 0.758 | 1.33 (0.13–14.01) 0.811 | 1.08 (0.37–3.15) 0.893 |

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; BMI, body mass index; KTxs, kidney transplant recipient.
Romania has 3 active kidney transplant centers and just over 3,000 KTx alive and in follow-up. This analysis from the largest Romanian transplant center, responsible for about half of the KTx in the country, provides a dynamic insight into this distinct patient population and the disease spanning over the first 12 months of the COVID-19 pandemic. The results suggest that the severity of the disease remained essentially unchanged and the patient profile did not change significantly over the first year. Most of the patients appeared to develop milder forms of the disease, which could be handled in an outpatient setting while maintaining a close contact between patients, primary health-care providers, and transplant physicians.

Part of the current data suggests that more KTx in the second wave developed milder disease forms with less pulmonary involvement. Unfortunately, the mortality during the second wave remained very high. Although the difference in mortality between the 2 waves did not reach statistical significance, the absolute numbers are strikingly similar to those of a larger Spanish cohort reporting 27 and 15% mortality during the first and second COVID waves, respectively [11]. This is in contrast with a smaller Belgian study, which found a similar mortality during the first 2 COVID waves [10]. During the first wave, Spain had disproportionately high prevalence, death toll, and mortality [29], whereas Romania and other East-European countries enforced a very strict lockdown and witnessed a limited outbreak. While refinements in patient management may have contributed to decreased mortality in the second wave, underdiagnosing mild cases during the first wave may have biased the analyses and results due to the identification of predominantly more severe cases seeking hospitalization.

As in previous other studies and larger analyses [3, 27, 30, 31], age remained the most important risk factor for unfavorable outcome. Furthermore, in line with several recent reports [29, 32], we found that the poor graft function has a significant predictive value for KTx death following COVID-19.

Our study has several limitations, mostly due to the unequal and relatively small size of the patient groups during the first 2 pandemic waves. The low number of cases during the first wave interfered with several statistical analyses. For this reason, we chose to extend “the first wave” beyond mid-June 2020, when the actual first wave actually ended, until late September 2020, when the second wave started. Moreover, insufficient testing during the early wave and asymptomatic cases may have led to an unknown number of undiagnosed cases. Asymptomatic COVID-19 in transplanted patients may range from 1.4 to 18% [11, 27] and may have represented a source of error. However, the noteworthy difference in infection numbers between periods with and without lockdown is likely due not to underdiagnosed cases but to the drastic lockdown measures enforced in the spring of 2020. This further emphasizes the life-saving potential of social distancing and stay-at-home orders as ways to minimize the

### Table 3. Multivariate logistic regression analysis for death after COVID-19 in the cohort of KTx and by waves

|                      | Coefficient | OR [95% CI] | p value | p value (Hosmer-Lemeshow test) |
|----------------------|-------------|-------------|---------|--------------------------------|
| **All**              |             |             |         |                                |
| Age, years           | 0.060       | 1.06 (1.01–1.11) | **0.013** |                                |
| eGFR baseline        | −0.050      | 0.95 (0.92–0.97) | **0.000** | 0.172                          |
| HT                   | 0.930       | 2.53 (0.53–12.14) | 0.247 |                                |
| Constant             |             |             |         |                                |
| **First wave**       |             |             |         |                                |
| Age, years           | 0.050       | 1.05 (0.95–1.16) | 0.358 |                                |
| eGFR baseline        | −0.060      | 0.95 (0.89–1.01) | 0.074 | 0.594                          |
| Hypertension         | n/r         | n/r         |         |                                |
| Constant             |             |             |         |                                |
| **Second wave**      |             |             |         |                                |
| Age, years           | 0.060       | 1.06 (1.01–1.12) | **0.031** |                                |
| eGFR baseline        | −0.060      | 0.94 (0.92–0.97) | **0.000** |                                |
| HT                   | 0.360       | 1.44 (0.28–7.35) | 0.664 |                                |
| Constant             |             | 0.102       |         |                                |

eGFR, estimated glomerular filtration rate; HT, hypertension; KTx, kidney transplant recipient.
patient risk of COVID-19 exposure. We did not include detailed laboratory data due to missing data, a large proportion of outpatients lacking sampling during COVID-19, or variable parameters and sampling frequency between different hospitals.

As with all the other COVID-19 studies, this report presents an evolutionary experience where cases were likely managed differently throughout the study. To the best of our knowledge, this is the third report worldwide and the first from Central and Eastern Europe to assess and compare the impact of first and second COVID-19 waves on transplant recipients. In line with others, the study reveals a progression toward a more rational and individualized patient management. Whereas the prevalence greatly increased, the mortality remained much higher than in nontransplanted patients.

**Statement of Ethics**

The study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The study protocol was reviewed and approved by the Ethical Review Committee of the Clinical Institute for Urology and Renal Transplantation, who waived the requirement for informed consent for the retrospective chart review (01/2021).

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

There is no funding source to be reported.

**Author Contributions**

F.L.E.: designed the study, collected and analyzed data, wrote the draft, and reviewed and approved the manuscript; S.D.B.: analyzed data, wrote the draft, and reviewed and approved the manuscript; A.M.: collected and analyzed data, and reviewed and approved the manuscript; A.D.E.: collected and analyzed data, and reviewed and approved the manuscript; C.C.: collected and analyzed data, and reviewed and approved the manuscript; M.L.: designed the study, collected and analyzed data, wrote the draft, and reviewed and approved the manuscript.

**References**

1. Kratzke IM, Rosenbaum ME, Cox C, Ollila DW, Kapadia MR. Effect of clear vs. standard covered masks on communication with patients during surgical clinic encounters: a randomized clinical trial. *JAMA Surg.* 2021 Mar 11;156:3728.

2. Panovska-Griffiths J, Kerr CC, Stuart RM, Mistry D, Klein DJ, Viner RM, et al. Determining the optimal strategy for reopening schools, the impact of test and trace interventions, and the risk of occurrence of a second COVID-19 epidemic wave in the UK: a modelling study. *Lancet Child Adolesc Health.* 2020 Nov;4(11):817–27.

3. Oltean M, Søfteland JM, Bagge J, Ekelund J, Felldin M, Schult A, et al. COVID-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic. *Infect Dis.* 2020 Nov;52(11):830–7.

4. Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. *Clin Infect Dis.* 2020;ciaa1097.

5. Ravanian R, Callaghan CJ, Mumford L, Ushiro-Lumb J, Thorburn D, Casey J, et al. SARS-CoV-2 infection and early mortality of wait-listed and solid organ transplant recipients in England: a national cohort study. *Am J Transpl.* 2020 Nov;20(11):3008–18.

6. Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences in ICU admissions during the first and second COVID-19 wave in Germany. *Lancet Respir Med.* 2021 Mar 5;9(21):e47–8.

7. Dutch COVID & Thrombosis Coalition; Kaptein FHJ, Stals MAM, Grootenboer M, Braken SJ, Bugggraaf JLI, van Bussel BCT, et al. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. *Thromb Res.* 2021 Mar;199:143–8.

8. Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R, Lombardy, Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation. *Infect Dis.* 2021 May;33(5):370–5.

9. Soriano V, Granado-Pinilla P, Sanchez-Santos M, Gomez-Gallego F, Barreto P, de Mendoza C, et al. Main differences between the first and second waves of COVID-19 in Madrid, Spain. *Int J Infect Dis.* 2021 Mar 5;105:374–6.

10. Georgy H, Devresse A, Scohy A, Kabamba B, Darius T, Bueni A, et al. The second wave of COVID-19 in a kidney transplant recipient cohort: a single-center experience in Belgium. *Transplantation.* 2021 Mar 1;105(3):e41–2.

11. Villanego F, Mazuecos A, Pérez-Flores IM, Morefo F, Andrés A, Jiménez-Martín C, et al.; Spanish Society of Nephrology COVID-19 Group. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: analysis of the Spanish registry. *Am J Transpl.* 2021 Mar 23.

12. Elec AD, Oltean M, Goldis P, Cismaru C, Lupşe M, Muntean A, et al. COVID-19 after kidney transplantation: early outcomes and renal function following antiviral treatment. *Int J Infect Dis.* 2021 Mar;104:426–32.

13. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ Accessed 2021 Mar 25.

14. Oltean S, Tătulescu D, Bondor C, Slavocovi A, Cismaru C, Lupse M, et al. Charlson’s weighted index of comorbidities is useful in assessing the risk of death in septic patients. *J Crit Care.* 2012;27(4):370–5.

15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–62.

16. Goodman KE, Magder LS, Baghdadi JD, Pineles L, Levine AR, Perencevich EN, et al. Impact of sex and metabolic comorbidities on COVID-19 mortality risk across age groups: 66,646 inpatients across 613 U.S. hospitals. *Clin Infect Dis.* 2020 Dec 18; ciaa1787.
17 Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.
18 Palmieri L, Palmer K, Lo Noce C, Meli P, Giuliano M, Floridia M, et al. Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. Aging Clin Exp Res. 2021 Jan;33(1):193–9.
19 Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transpl. 2020 Jul;20(7):1800–8.
20 Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020 Jun;97(6):1083–8.
21 Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transpl. 2020 Jul;20(7):1849–58.
22 Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020;77(20):748–54
23 Maggiore U, Abramowicz D, Crespo M, Marrat C, Mjoen G, Peruzzi L, et al. How should I manage immunosuppression in a kidney transplant patient with COVID-19? An Eredita descartes expert opinion. Nephrol Dial Transpl. 2020;35(6):899–904.
24 Fellen D, Softeland JM, Magnusson J, Ekberg J, Karason K, Schult A, et al. Initial report from a Swedish high-volume transplant center after the first wave of the COVID-19 pandemic. Transplantation. 2021;105(1):108–14.
25 Husain SA, Dube G, Morris H, Fernandez H, Chang JH, Paget K, et al. Early outcomes of outpatient management of kidney transplant recipients with coronavirus disease 2019. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1174–8.
26 Lubetzky M, Aull MJ, Craig-Schapiro R, Lee JR, Marku-Podvorica J, Salinas T, et al. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York city transplant center. Nephrol Dial Transpl. 2020;35(7):1250–61.
27 Softeland JM, Friman G, von Zur-Mühlen B, Ericzon BG, Wallquist C, Karason K, et al. COVID-19 in solid organ transplant recipients: a national cohort study from Sweden. Am J Transpl. 2021 Apr 3.
28 Tabacof L, Kellner C, Breymen E, Dewil S, Braren S, Nasr L, et al. Remote patient monitoring for home management of coronavirus disease 2019 in New York: a cross-sectional observational study. Telemed J E Health. 2020 Oct 13;27:6418.
29 García-Basteiro AL, Legido-Quigley H; 20 signatories. Evaluation of the COVID-19 response in Spain: principles and requirements. Lancet Public Health. 2020 Nov;5(11):e575.
30 Kute VB, Bhalia AK, Guleria S, Ray DS, Bahadur MM, Shingare A, et al. Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: a multicenter cohort study from India. Transplantation. 2021 Apr 1;105(4):851–60.
31 Azzi Y, Parides M, Alani O, Loarte-Campos P, Bartash R, Forest S, et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int. 2020 Dec;98(6):1559–67.
32 Linares L, Cofan F, Diekmann F, Herrera S, Marcos MA, Castel MA, et al. A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. PloS One. 2021 Mar 5;16(3):e0247251.